<DOC>
	<DOCNO>NCT00678704</DOCNO>
	<brief_summary>The superiority BAY 38-9456 10 mg 20 mg regimen placebo , 20 mg 10 mg confirm patient diabetes mellitus suffer erectile dysfunction . There large difference incidence rate drug-related adverse event 10 mg 20 mg regimen . Overall tolerability consider good regimen .</brief_summary>
	<brief_title>BAY38-9456 - Pivotal Trial Diabetes Patient</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Male erectile dysfunction 3 year accord National Institutes Health ( NIH ) Consensus Statement ( inability attain and/or maintain penile erection sufficient satisfactory sexual performance ) Diabetes 3 year Following label Japanese package insert vardenafil 5/10 mg , except high dose Spinal cord injury History surgical prostatectomy ( exclude TURP ) Patients HbA1c &gt; 12 % Visit 1 Use nitrate Use potent CYP3a4 inhibitor Severe liver disease Presence Peyronie 's Disease</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Vardenafil</keyword>
	<keyword>PDE5 inhibitor</keyword>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Sexual Dysfunction</keyword>
</DOC>